Yin-Dan Xin-Nao-Tong Capsule Combined with Routine Modern Therapies for Treatment of Type-2 Diabetics Mellitus Complicated with Coronary Heart Disease：A Systematic Review
10.11842/wst.2014.09.026
- VernacularTitle:银丹心脑通软胶囊治疗2型糖尿病合并冠心病临床疗效的系统评价
- Author:
Guiqin XU
;
Xueling LI
;
Jun YANG
;
Bin HE
;
Huan WANG
;
Wenjing JIANG
;
Hui JIANG
- Publication Type:Journal Article
- Keywords:
Yin-Dan Xin-Nao-Tong Capsule;
type-2 diabetes mellitus;
coronary heart disease;
systematic review;
randomized controlled trial
- From:
World Science and Technology-Modernization of Traditional Chinese Medicine
2014;(9):2002-2008
- CountryChina
- Language:Chinese
-
Abstract:
This article was aimed to assess the effectiveness and safety of Y in-Dan Xin-Nao-Tong (YDXNT) Cap-sule combined with routine modern therapies for treatment of type-2 diabetes mellitus (T2MD) complicated with coronary heart disease (CHD). Databases including CBMDisc, CMAC, CNKI, VIP, Wanfang Data, PubMed, EMbase, and Web of Science were electronically searched from inception to December 2013. Randomized controlled trials (RCTs) on YDXNT capsule combined with routine modern therapies for treatment of T2MD complicated with CHD were included. Two reviewers independently screened literature according to the inclusion and exclusion criteria, ex-tracted data, and assessed the methodological quality of included studies. Then, meta-analysis was performed using RevMan 5.1.0 software. The results showed that a total of 9 RCTs with 667 T2MD with CHD cases were included. The results of meta-analysis indicated that the total effective rate of YDXNT capsule combined with routine modern therapies was significant higher than the routine treatment for T2MD complicated with CHD treatment with statistical significance (OR = 4.01, 95%CI [2.37-6.79], P< 0.000 01). It showed that YDXNT capsule combined with routine modern therapies can control angina pectoris. Due to limitation of included data, controlling of the duration of angina pectoris, the attack frequency of angina pectoris, and fasting blood glucose, may be better than the routine treatment group with significant differences. YDXNT capsule can improve hemorheology indices and reduce high condensation state among CHD with T2DM patients in order to relieve angina pectoris. It was concluded that on the basis of current clinical evidences, YDXNT capsule had better treatment effect than the routine treatment group in the treatment of CHD with T2DM. However, the results have certain limitations. It still required double-blind multi-center RCTs with high quality, large samples for further verification.
